Oriheal Pimotone 2.5mg is a prescription-only veterinary cardiovascular medication formulated for the clinical management and treatment of congestive heart failure (CHF) and structural heart disease in dogs and cats. The active pharmaceutical ingredient, Pimobendan (2.5mg), is a premier "inodilator" that operates via a crucial dual mechanism of action: it acts as a calcium sensitizer to directly enhance myocardial contractility (positive inotropy) while simultaneously functioning as a phosphodiesterase III (PDE3) inhibitor to dilate peripheral and systemic blood vessels.

This targeted, mid-strength formulation minimizes resistance in systemic blood pathways, decreases the preload and afterload on weak heart chambers, and optimizes total cardiac output without increasing myocardial oxygen consumption. In canine patients, Pimotone 2.5mg is a mainstay treatment for small to medium-sized breeds suffering from congestive heart failure secondary to Dilated Cardiomyopathy (DCM) or Atrio-Ventricular Valvular Insufficiency (AVVI/MMVD). It is also prescribed in pre-clinical stages to delay the onset of clinical heart failure in cases with confirmed cardiac enlargement. In feline healthcare, it serves under strict veterinary discretion for advanced myocardial pathologies showing systolic dysfunction. Formulated as a palatable chewable tablet, it noticeably reduces severe clinical symptoms such as chronic coughing, breathlessness, and extreme lethargy, significantly enhancing the animal's daily quality of life and long-term survival time.